Amicus Therapeutics (NASDAQ: FOLD) reported Q3 EPS of $0.10, $0.10 better than the analyst estimate of $0.00. Revenue for the quarter came in at $141.52 million versus the consensus estimate of $134.93 million.

2024 Financial Guidance:

Total Revenue Growth: 30% to 32%
Galafold Revenue Growth: 16% to 18%
Pombiliti + Opfolda Revenue: $69M to $71M
Non-GAAP Operating Expenses $340M to $350M

For earnings history and earnings-related data on Amicus Therapeutics (FOLD) click here.